Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.74 |
| ▸ | MEN1 | O00255 | 7/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | HTT | P42858 | 3/20 | 0.74 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | INSR | P06213 | 1/20 | 0.58 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.55 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.55 |
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526639 | 1.00 | MAPT (0.74) | MAPTKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL9516881 | 0.88 | MAPT (0.66) | MAPTKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL9516889 | 0.88 | MAPT (0.66) | MAPTKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL2830702 | 0.88 | MAPT (0.73) | MAPTKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL23111697 | 0.88 | MAPT (0.77) | MAPTKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL19695963 | 0.88 | MAPT (0.77) | MAPTKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL17576070 | 0.86 | MAPT (0.79) | MAPTKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL16180705 | 0.86 | MAPT (0.79) | MAPTKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL16180704 | 0.86 | MAPT (0.79) | MAPTKMT2AMEN1RAB9AKDM4E | |
| SCHEMBL9607131 | 0.86 | MAPT (0.60) | MAPTKMT2AMEN1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | claimed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | claimed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | claimed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | claimed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | claimed |
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | disclosed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | disclosed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | disclosed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | disclosed |
| US-8524682-B2 | Compositions and methods for inhibiting EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | US | disclosed |
| US-20100222420-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2009006577-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090012031-A1 | EZH2 Cancer Markers | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | EZH2, BMI1, EZH1 | MAPT 3335/4885KMT2A 23/4885MEN1 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.